Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Postprandial Glycemic and Physiological Responses to Walking With a Wearable Hip Exoskeleton in Patients With Type 2 Diabetes (Bot-Fit T2D St)

5. juli 2026 oppdatert av: CHA University

Postprandial Glycemic and Physiological Responses to Walking With a Wearable Hip Exoskeleton in Patients With Type 2 Diabetes: A Randomized Crossover Proof-of-Concept Study

This randomized crossover proof-of-concept study evaluated the effects of walking with a wearable hip exoskeleton on postprandial glycemic and physiological responses in patients with type 2 diabetes. Participants completed four experimental conditions: seated control, walking without the wearable hip exoskeleton, walking with the Bot-Fit device in Aqua mode, and walking with the Bot-Fit device in Boost mode. The primary aim was to determine whether walking with the wearable hip exoskeleton alters postprandial glucose responses compared with seated control and conventional walking conditions in patients with type 2 diabetes.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This study investigated whether walking with a wearable hip exoskeleton could modulate postprandial glycemic and physiological responses in patients with type 2 diabetes. Using a randomized crossover design, each participant completed four experimental conditions in a controlled laboratory setting: seated control, walking without the wearable hip exoskeleton, walking with the Bot-Fit device in Aqua mode, and walking with the Bot-Fit device in Boost mode.

Postprandial glucose responses were assessed after meal ingestion during each experimental trial. Physiological responses, including heart rate and perceived exertion, were also evaluated to compare the metabolic and perceptual demands of walking with and without the wearable hip exoskeleton. The study was designed as a proof-of-concept trial to examine whether wearable hip exoskeleton-assisted walking may influence postprandial glucose regulation in patients with type 2 diabetes.

Studietype

Intervensjonell

Registrering (Faktiske)

14

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Sør -Korea
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Sør -Korea, 13503
        • CHA University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Adults diagnosed with type 2 diabetes mellitus.
  • Participants who were able to complete walking trials with and without the wearable hip exoskeleton.
  • Participants who provided written informed consent before participation.

Exclusion Criteria:

  • Participants with unstable cardiovascular, neurological, or musculoskeletal conditions that could affect walking ability or safe participation.
  • Participants with conditions that could interfere with postprandial glucose assessment.
  • Participants who were unable to safely use the wearable hip exoskeleton.
  • Participants who were unable to comply with the study procedures.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Non-Assisted Walking
Participants performed 30 minutes of overground walking without wearing the Bot-Fit device.
Atferdsmessig: Non-Assisted Walking
Participants performed 30 minutes of overground walking without wearable hip exoskeleton assistance during the postprandial period.
Eksperimentell: Bot-Fit Aqua Mode
Participants performed 30 minutes of overground walking while wearing the Bot-Fit device in Aqua mode.
Enhet: Bot-Fit Aqua Mode
Participants performed 30 minutes of overground walking while wearing the Bot-Fit wearable hip exoskeleton in Aqua mode during the postprandial period.
Eksperimentell: Bot-Fit Boost Mode
Participants performed 30 minutes of overground walking while wearing the Bot-Fit device in Boost mode.
Enhet: Bot-Fit Boost Mode
Participants performed 30 minutes of overground walking while wearing the Bot-Fit wearable hip exoskeleton in Boost mode during the postprandial period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incremental Area Under the Curve for Postprandial Glucose
Tidsramme: Up to 120 minutes after meal ingestion during each experimental trial
Incremental area under the curve for postprandial glucose was calculated during the postprandial measurement period for each experimental condition.
Up to 120 minutes after meal ingestion during each experimental trial

Sekundære resultatmål

Resultatmål
Tidsramme
Peak Postprandial Glucose Concentration
Tidsramme: Up to 120 minutes after meal ingestion during each experimental trial
Up to 120 minutes after meal ingestion during each experimental trial
Heart Rate Response
Tidsramme: Up to 30 minutes
Up to 30 minutes
Rating of Perceived Exertion
Tidsramme: Up to 30 minutes
Up to 30 minutes

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

CHA University

Samarbeidspartnere

Samsung Electronics

Etterforskere

  • Hovedetterforsker: Seung-Bo Park, Ph.D, CHA University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. mars 2026

Primær fullføring (Faktiske)

24. mai 2026

Studiet fullført (Faktiske)

24. mai 2026

Datoer for studieregistrering

Først innsendt

5. juli 2026

Først innsendt som oppfylte QC-kriteriene

5. juli 2026

Først lagt ut (Faktiske)

9. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • BOTFIT-T2D-2025
  • S-2025-0600-000-1 (Annet stipend/finansieringsnummer: Samsung Electronics)
  • CHAMC 1044308-202503-BR-237-02 (Annen identifikator: CHA University Medical Center IRB approval number)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified individual participant data underlying the main results of the study may be shared upon reasonable request. The shared data may include postprandial glucose responses, heart rate, blood lactate, rating of perceived exertion, and relevant demographic and physiological variables after deidentification.

IPD-delingstidsramme

Data may be made available beginning 6 months after publication of the main study results and for up to 3 years thereafter.

Tilgangskriterier for IPD-deling

Data may be shared with qualified researchers who submit a reasonable research proposal to the corresponding author. Access will be granted only after review and approval by the investigators and, where required, appropriate institutional or ethics committee approval. Data will be shared only for scientific purposes and in a deidentified form.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Type 2 diabetes mellitus (T2DM)

Kliniske studier på Non-Assisted Walking

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Ukraine

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere